Helen Katrina Tayton-Martin

Chief Operating Officer, Adaptimmune (United Kingdom).

Companies

Evaxion A/SChief executive officer Mar 31, 2026 to now¹
Adaptimmune (United Kingdom)Chief Business Officer Jan 17, 2018 to Jan 17, 2024²
Trillium Therapeutics Inc.Board member Jan 4, 2021 to Nov 19, 2021³
Adaptimmune (United Kingdom)Chief operating officer Jan 4, 2016 to Jan 18, 2017⁴

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Evaxion A/S EVAX2,286,150 shares⁵$7.7M at $3.35Mar 31, 2026

As of each latest filing. The line shows shares held over time.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGAREvaxion A/S, Chief executive officer
2
SEC EDGARAdaptimmune (United Kingdom), Chief Business Officer
3
SEC EDGARTrillium Therapeutics Inc., Board member
4
SEC EDGARAdaptimmune (United Kingdom), Chief operating officer
5
SEC EDGAREvaxion A/S shares after the filing of Mar 31, 2026